Other analysts have also issued reports about the stock. HC Wainwright set a $25.00 target price on shares of Voyager Therapeutics and gave the company a buy rating in a research report on Friday, November 30th. Zacks Investment Research upgraded shares of Voyager Therapeutics from a hold rating to a buy rating and set a $13.00 target price on the stock in a report on Saturday, November 17th. ValuEngine lowered shares of Voyager Therapeutics from a strong-buy rating to a buy rating in a research report on Monday, September 17th. BidaskClub raised shares of Voyager Therapeutics from a sell rating to a hold rating in a report on Saturday, September 29th. Finally, Morgan Stanley set a $13.00 price target on shares of Voyager Therapeutics and gave the company a hold rating in a research note on Thursday, November 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $25.56.
NASDAQ:VYGR opened at $9.10 on Thursday. Voyager Therapeutics has a 52 week low of $8.30 and a 52 week high of $31.91. The stock has a market capitalization of $307.99 million, a price-to-earnings ratio of -3.45 and a beta of 2.73.
A number of institutional investors have recently bought and sold shares of the business. Rhumbline Advisers boosted its position in Voyager Therapeutics by 18.3% in the 2nd quarter. Rhumbline Advisers now owns 20,258 shares of the company’s stock valued at $396,000 after buying an additional 3,132 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Voyager Therapeutics by 17.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 101,576 shares of the company’s stock worth $1,985,000 after acquiring an additional 14,849 shares during the period. Swiss National Bank raised its position in shares of Voyager Therapeutics by 20.1% in the second quarter. Swiss National Bank now owns 35,300 shares of the company’s stock valued at $690,000 after buying an additional 5,900 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at approximately $594,000. Finally, BlackRock Inc. raised its position in Voyager Therapeutics by 28.3% during the second quarter. BlackRock Inc. now owns 1,845,706 shares of the company’s stock valued at $36,066,000 after purchasing an additional 407,677 shares in the last quarter. 88.57% of the stock is owned by hedge funds and other institutional investors.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Featured Story: How is Preferred Stock Different from Common Stock?
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.